CD86 and urinary bladder carcinoma: To further investigate the immunogenic properties of NCTD-treated BC cells, mouse dendritic cells (mDC) were challenged with MB49 mouse bladder cancer cells pretreated with or without NCTD, then the mDC maturation makers (CD80+/CD11c+ or CD86+/CD11c+) were analyzed by flow cytometry.